Baldwin Wealth Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Baldwin Wealth Partners’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-47	Closed	-$75	–	803
2023 Q1	$75	Hold	47	–	–	﹤0.01%	798
2022 Q4	$69	Hold	47	–	–	﹤0.01%	779
2022 Q3	$0	Hold	47	–	–	﹤0.01%	711
2022 Q2	$0	Hold	47	–	–	﹤0.01%	712
2022 Q1	$0	Hold	47	–	–	﹤0.01%	705
2021 Q4	$0	Hold	47	–	–	﹤0.01%	661
2021 Q3	$0	Hold	47	–	–	﹤0.01%	678
2021 Q2	$1K	Hold	47	–	–	﹤0.01%	655
2021 Q1	$0	Hold	47	–	–	﹤0.01%	639
2020 Q4	$0	Hold	47	–	–	﹤0.01%	569
2020 Q3	$0	Sell	47 -1	-2%	-$9	﹤0.01%	553
2020 Q2	$0	Hold	48	–	–	﹤0.01%	560
2020 Q1	$1K	Hold	48	–	–	﹤0.01%	540
2019 Q4	$1K	Hold	48	–	–	﹤0.01%	534
2019 Q3	$1K	Hold	48	–	–	﹤0.01%	515
2019 Q2	$1K	Hold	48	–	–	﹤0.01%	504
2019 Q1	$2K	Hold	48	–	–	﹤0.01%	495
2018 Q4	$1K	Hold	48	–	–	﹤0.01%	496
2018 Q3	$3K	Hold	48	–	–	﹤0.01%	500
2018 Q2	$4K	Hold	48	–	–	﹤0.01%	486
2018 Q1	$5K	Buy	+48	New	+$8.23K	﹤0.01%	453

Other funds holding VIRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Baldwin Wealth Partners's VIRX Position: Q2 2023 in Review

Baldwin Wealth Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2023, closing a stake of 47 shares — an estimated $75 sold.

Baldwin Wealth Partners first reported a position in VIRX in Q1 2018 and held it in 21 quarters. The position peaked at $5K in Q1 2018. 41 funds tracked by Wall St. Rank hold VIRX as of Q2 2023.

Baldwin Wealth Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Baldwin Wealth Partners sold 47 Viracta Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $75.
Baldwin Wealth Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2018 and held it in 21 quarters.
Baldwin Wealth Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $5K in Q1 2018.
41 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Baldwin Wealth Partners's 13F filing for Q2 2023, filed 14 Jul 2023.